				520 Rec'd PUT/PT	
-	FORM I	PTO-139 0-95)	90 (Modified) U.S. DEPARTMENT		ATTORNEY CKET NUMBER
	ĺ	TF		TO WE UNITED STATES	SCH 1653
1	i		DESIGNATED/ELECTI	ED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (IF KNOWN SEE 37 CFR
	i		CONCERNING A FILIN	NG UNDER 35 U.S.C. 371	09/44024
R	INTE		TIONAL APPLICATION NO. PCT/EP98/03658	INTERNATIONAL FILING DATE 18 June 1998	PRIORITY DATE CLAIMED 20 June 1997
		E OF I	NVENTION		
	USE	OF !	INTRAVENOUS CONTRAS	ST MEDIA FOR PROJECTION MAMN	ЮGRAPHY
ŗ				IPE	
			T(S) FOR DO/EO/US PECK et al.	DEC 2 0 1999	
Ì	Appli	icant l	herewith submits to the United Sta	ates Designated/Elected/Office (DO/B) US) the	e following items and other information:
ı	1.	\boxtimes		items concerning a filing under 35 U.S.C. 371.	-
	2.			PUENT submission of items concerning a filing	2 under 35 U.S.C. 371.
	3.		This is an express request to beg	tin national examination procedures (35 U.S.C. of the applicable time limit set in 35 U.S.C. 37	371(f)) at any time rather than delay
	4.	\boxtimes			19th month from the earliest claimed priority date
ű	5.	\boxtimes		lication as filed (35 U.S.C. 371 (c) (2))	
1	l		a. is transmitted herewith	(required only if not transmitted by the Interna	ational Bureau).
, and the second	ı		-	y the International Bureau.	
11 100 11 100 100 100 100 100 100 100 10	ı			application was filed in the United States Received	_ , ,
1, 1	6.	\boxtimes		1 Application into English (35 U.S.C. 371(c)(2)).
23 25	7.	×	A copy of the International Search		
d'in any and and a	8.	X		e International Application under PCT Article 1	
	ı			h (required only if not transmitted by the Intern	national Bureau).
il in the	ı		_	by the International Bureau.	
i dinasi Marija				owever, the time limit for making such amendm	nents has NOT expired.
#	-	_	d. A have not been made and		
H II B	9.			to the claims under PCT Article 19 (35 U.S.C.	371(c)(3)).
- 1	10.		An oath or declaration of the inve		
suin .	11.			minary Examination Report (PCT/IPEA/409).	
16 (con);	12.	Ц	A translation of the annexes to the (35 U.S.C. 371 (c)(5)).	ne International Preliminary Examination Repor	rt under PCT Article 36
· w	_		3 to 18 below concern document		
	13.			ement under 37 CFR 1.97 and 1.98.	
ļ	14.			ording. A separate cover sheet in compliance w	with 37 CFR 3.28 and 3.31 is included.
1	15.		A FIRST preliminary amendmen		
1	.,	_	A SECOND or SUBSEQUENT	preliminary amendment.	
	16.		A substitute specification.		
- 1	17. 18.		A change of power of attorney ar		
- 1	18.	∐ ⊠	Certificate of Mailing by Express Other items or information:	s Maii	
1	17.	تخا	Letter		
			Letter Drawings 1 sheet PCT/IB/304		
-					
-					
1					_
1					· ·
١					
- 1			L		

			4_0	180'a P	CT/	PTO ZUU	C 1999
J.S. APPLICATION	NO. (IF KNOWN, SEE ST CFR	PCT/E	APPLICAT P98/0365				DOCKET NUMBER H 1653
20. The fo	llowing sees are submitted:.					CALCULATION	S PTO USE ONLY
	L FEE (37 CFR 1.492 (a) (1						
	ort has been prepared by the El			\$840.0	10		
	Il preliminary examination fee		1.482)	\$670.00			
☐ No internate but internate	onal preliminary examination ional search fee paid to USPTO	fee paid to USPTO (37 C O (37 CFR 1.445(a)(2))	FR 1.482) \$760.0	00		
☐ Neither inte internationa	rnational preliminary examina l search fee (37 CFR 1.445(a)(tion fee (37 CFR 1.482) r 2) paid to USPTO	or	\$970.0	00		
☐ International and all clair	Il preliminary examination fee ns satisfied provisions of PCT	paid to USPTO (37 CFR Article 33(2)-(4)	1.482)	\$96.0	0		
	ENTER APPROPI	RIATE BASIC FE	E AM	OUNT =	:	\$840.00	:
	00 for furnishing the oath or derliest claimed priority date (3)		□ 20	0 🛛 3	0	\$130.00	
CLAIMS	NUMBER FILED	NUMBER EXT	'RA	RATI	3		
Total claims	17 - 20 =	0		x \$18.0	00	\$0.00	
Independent claims	1 - 3 =	0		x \$78.0	00	\$0.00	
Multiple Depender	nt Claims (check if applicable					\$0.00	
		OF ABOVE CALC			=_	\$970.00	
Reduction of 1/2 for must also be filed	or filing by small entity, if app (Note 37 CFR 1.9, 1.27, 1.28)	licable. Verified Small E (check if applicable).	· · · · · · · · · · · · · · · · · · ·			\$0.00	
			SUB	FOTAL		\$970.00	
Processing fee of \$ months from the ea	130.00 for furnishing the Engl rliest claimed priority date (3)	ish translation later than 7 CFR 1.492 (f)).	□ 20	0 🗆 3	0 +	\$0.00	
		TOTAL NAT	IONAI	LFEE		\$970.00	
Fee for recording the accompanied by an	ne enclosed assignment (37 CF appropriate cover sheet (37 C	R 1.21(h)). The assignmer R 3.28, 3.31) (check if	ent must l applicabl	ne l e).		\$0.00	1
		TOTAL FEES	ENCL	OSED		\$970.00	
						Amount to be: refunded	\$
						charged	\$
☐ Please cha	the amount of \$970.00 rge my Deposit Account No. te copy of this sheet is enclose		fees is enc			to cover the abo	ve fees.
Aduplica	te copy of this sheet is enclosed	1.					
The Comm	nissioner is hereby authorized t	o charge any fees which i	nay be re	quired, or c	redit a	ny overpayment	
to Deposit	Account No. 13-3402	A duplicate copy of th	is sheet is	s enclosed.			
NOTE: Where an 1.137(a) or (b)) m	appropriate time limit unde ust be filed and granted to re	r 37 CFR 1.494 or 1.495 store the application to	has not l	been met, a	petiti	on to revive (37 CF	R
	ESPONDENCE TO:					`	
	E, ZELANO & BRANIGAN	P.C	l		(· 	· <u>-</u>
Arlington Courth	-	1		SIGNAT	URE	\prec	
2200 Clarendon I	Anthony J. Zelano						
Arlington, Virgin (703) 243-6333	ia 444UI	!		NAME		····	
				19,544			
				<u> </u>	RATIO	ON NUMBER	
				20 Dece	mber	1999	
Filed: 12/20/99 AJZ:jvbp				DATE			

USE OF INTRAVENOUS CONTRAST MEDIA FOR PROJECTION MAMMOGRAPHY

The invention relates to the use of intravenous contrast media for projection mammography as well as new devices for projection mammography.

Prior Art

For a decade, mammography has been an established and steadily improved x-ray technique for early detection, radiologic identification, characterization, and localization of mammary tumors. In many respects, it is unparalleled in its performance and availability to patients. The greatest drawback is its imperfect detection sensitivity for tumors that are small and without detectable microlime.

Early on, attempts were made to use contrast media to improve projection mammography. For this purpose, suitable preparations were introduced into the milk ducts, and their dispersion into the breast was used for detecting and characterizing lesions. The work of R. Bjørn-Hansen provides a survey: Contrast-Mammography, Brit. J. Radiol. 38, 947-951, 1965. The technique is also known as galactography. The contrast is achieved by concentrated iodine-containing contrast media (> 100 mg of iodine/ml). In addition, contrast media were injected directly into suspicious or tumorous lesions of the

breast either to characterize the latter (e.g., Lehto, M. and Mathiesen, T. I.: Adenography: An Ancillary Diagnostic Method of Circumscribed Lesions of the Breast with a Positive Contrast Agent, Breast Dis, 6, 259-268, 1993) or to label the latter (e.g., Raininko, R.; Linna, M. I.; Rasanen, O: Preoperative Localization of Nonpalpable Breast Tumors. Acta. Chir. Scand, 142, 575-578, 1976). In both cases, undiluted, commercially available contrast media are used directly for visualization.

The intravenous administration of x-ray contrast media for visualization of parenchymatous processes in projection radiography is the very rare exception. It is successful only if the contrast medium actively accumulates in a tissue or organ. In this respect, there are to date two examples: The visualization of the healthy renal parenchyma by the now commonly used urographic agents and the visualization of the healthy liver and spleen parenchyma by emulsions or suspensions of x-ray-opaque substances. Both methods are no longer used (liver, spleen) or are used only in exceptional cases (kidney). It has never been possible to use intravenously administered x-ray contrast media for direct contrasting of tumors of relevant size in projection radiography.

Computer tomography and especially magnetic resonance tomography are known for their very much higher measuring sensitivity for contrast media. It was still a surprise, however, that both techniques made it possible to detect mammary tumors with great reliability after intravenous contrast medium injection (Gisvold, J. J.; Karsell, P. R.; Reese, E.C.: Clinical

Evaluation of Computerized Tomographic Mammography. Mayo Clin Proc 52, 181-185, 1977; Teifke, A.; Schweden, F.; Cagil, H.; Kanczor, H. U; Mohr, W.; Thelen, M.: Spiral-Computertomographie der Mamma [Spiral Computer Tomography of the Breast]. Fortschr. Röntgenstr 161, 495-500, 1994; Heywang, S. H.; Hahn, D.; Schmidt, H.; Krischke, I.; Eiermann, W.; Bassermann, R.; Lissner, J.: MR Imaging of the Breast Using Gadolinium DTPA. J. Comp Ass Tomogr 10, 199-204, 1986.

Even after publication of the contrast enhancement of mammary tumors by intravenous contrast medium administration in CT, the detection sensitivity of projection mammography for iodine-containing contrast media was previously regarded as too low to be able to use this CT-detectable effect in mammography. The usability of the bromine-containing contrast media that are known as less x-ray-opaque or the metal chelate solutions that are available only in lower concentrations for this application is thus even more unlikely. Fritz, S. L.; Chang, C. H. J.; and Livingston, W. H.: (Scatter/Primary Ratios for X-Ray Spectra Modified to Enhance Iodine Contrast in Screen-film Mammography, Med Phys 10, 866-870, 1983) therefore investigate the question of whether a radiation quality that is more suitable for the absorption spectrum of the iodine can be produced by various physical measures. The results of this work still cannot be considered satisfactory, but it is believed that there is some chance for further optimization of the x-ray spectrum.

In the mid-1980's, an attempt was made to use digital subtraction angiography (DSA) with intravenous injection of

contrast media. The process was not accepted since its reliability and sensitivity were too low, and in any case further testing is required (Dean, P.B.; Sickles, E.A.: Invest Radiol 20, 698-699, 1985).

The above-mentioned methods have advantages over conventional projection mammography, but also significant drawbacks such as high cost and limited availability, inadequate detection of the microlime that is important for tumor diagnosis, low spatial resolution, extended testing times, poor accessibility for biopsies, or higher radiation exposure. Although not every drawback applies to every technique, MR and, even more, CT are now used only in a very small proportion of the patients in question, and DSA is virtually not used at all for detecting mammary tumors.

Because of its almost universal availability, low cost and in many respects high performance, an improvement in the projection mammography that is introduced is therefore of great importance with respect to more reliable detection of tumors. In this respect, many tests have already been done. In particular, the recording technique and the film material that is used have been optimized over the decades; and xeroradiography has been tried and tested. New receiver systems and digitization promise further progress. Nevertheless, projection mammography, as far as can be seen now, clearly lies under the sensitivity of the best method to date, contrast-enhanced magnetic resonance tomography.

Description of the Invention

It has now been found, completely surprisingly enough, that projection radiography, which is known as quite contrast mediuminsensitive, can, in special cases, improve projection mammography by intravenous contrast medium administration, although the contrast media are very strongly diluted on the way through heart and lung and are not known to actively concentrate in mammary tumors.

The invention therefore relates to the use of intravenous contrast media for the production of a diagnostic agent for projection mammography.

Through the additional intravenous administration of contrast media, projection mammography achieves a sensitivity that is comparable to that of the most modern processes such as magnetic resonance tomography (MRT) while being considerably more versatile and avoiding the costs of MRT. The new process can be implemented simply and without special stress on the patients and provides a significant improvement in

- a) sensitivity to the detection of focal lesions in the breast, and
- b) additional information on the nature of lesions detected previously.

Its use according to the invention can be done with now available devices and agents, e.g., as follows, if the devices are operated with low radiation energy -- as is common in projection mammography.

The measuring process is preferably performed as follows:

- 1) A normal mammogram is recorded (pre-contrast image).
- 2) The patient receives a commonly used urographic x-ray contrast medium at a dose of about 0.5 g to 1.5 g of iodine/kg of body weight that is quickly injected intravenously or infused.
- 3) 30 seconds to 1 minute after the end of the injection, a second mammogram is recorded (post-contrast image). Other images are optionally recorded up to about 5 minutes after the end of the injection, which, if necessary, can provide additional information on the properties of the lesion.

Devices and device settings of less than 50 kV are suitable for use according to the invention; the use of radiation that corresponds to 20 kV to 40 kV is preferred; a radiation energy of 25 kV to 35 kV is especially preferred.

For use according to the invention, all compounds are suitable that are commonly used for the production of water-soluble urographic contrast media. As examples, there can be mentioned: meglumine or lysine diatrizoate, iothalamate, ioxithalamate, iopromide, iohexol, iomeprol, iopamidol, ioversol, iobitridol, iopentol, iotrolan, iodixanol, and ioxilan (INN).

Iodine-free compounds can also be used, however, such as,
e.g.:

 Contrast media that contain bromine as an imaging element,

- 2. Contrast media that contain elements of atomic numbers 34, 42, 44-52, 54-60, 62-79, 82, or 83 as imaging elements,
- 3. Contrast media that contain chelate compounds of elements of atomic numbers 56-60, 62-79, 82, or 83 as imaging elements.

The invention therefore also relates to the use of such iodine-free compounds.

The now commonly used urographic x-ray contrast media are extremely well suited for the above-described process. It was found, surprisingly enough, that unlike in almost every other x-ray process in projection mammography, the element iodine can be exchanged completely or partially for the element bromine. This has also been discussed specifically in the past but has not proven its value in any x-ray process because of the significantly lower radiation absorption of bromine compared to iodine. In this respect, projection mammography represents an exception. It is a novel, surprising use for the compounds that are described in, e.g., EP 0 118 348 A1.

In addition, contrast media that can be excreted and are tolerable and are based on other opacifying elements, molecular and supramolecular structures are also suitable for use according to the invention.

As opacifying elements, mainly those with atomic numbers 34, 42, 44-60, 62-79, 82, or 83 are suitable. The opacifying elements can be bonded covalently to organic molecules or can be present as complexes or integrated into macromolecular

structures. Substances with molecular weights of 10,000 to 80,000 D are especially advantageous. In addition, the individual contrast medium molecule components can be of larger structures, such as associates, liposomes, emulsion droplets and microparticles or nanoparticles (Parvez, Z.; Moncada, R.; Sovak, M., edts.: Contrast Media: Biological Effects and Clinical Application. Vol. III, CRC Press, Boca Raton, Florida 1987, 73-130).

The medium is prepared in a pharmaceutically usual form in physiologically compatible vehicle media, preferably water, while using commonly used adjuvants such as stabilizers (e.g., complexes, complexing agents, antioxidants), buffers (e.g., tris, citrate, bicarbonate), emulsifiers and substances for adaptation to osmolality and electrolyte content as required.

Preferred are contrast media with concentrations of 100 mg of iodine/ml to 500 mg of iodine/ml; especially preferred are nonionic x-ray contrast media with 200 mg of iodine/ml to 400 mg of iodine/ml or a corresponding x-ray opacity when another radiation-absorbing element is selected. The agent can be administered at a dose of 150 to 1500 mg of iodine/kg of body weight (KG).

When bromine-containing compounds are used according to the invention, a concentration of 100 to 500 mg of bromine/ml in the contrast medium is preferred. The dose that can be administered is 100 to 1500 mg of bromine/kg of body weight.

When compounds of the elements of atomic numbers 34, 42, 44-52, 54-60, 62-79, 82, or 83 are used according to the invention,

a concentration of 10 mmol to 2 mol/l -- relative to the imaging element -- in the contrast medium is preferred. The dose that can be administered is 0.1 to 2 mmol/kg of body weight (relative to the imaging element). The range of 0.2 to 0.6 mmol/kg of body weight is preferred.

When the chelate compounds of the elements of atomic numbers 56-60, 62-79, 82, or 83 are used according to the invention, a concentration of 10 mmol to 2 mol/l -- relative to the imaging element -- in the contrast medium is preferred. The dose that can be administered is 0.1 to 2 mmol/kg of body weight (relative to the imaging element). The range of 0.2 to 0.6 mmol/kg of body weight is preferred.

A very advantageous variant of intravenous contrastprojection mammography in the use according to the invention
relates to the use of the subtraction technique, which to date
has not been introduced in projection mammography. Corresponding
processes have proven their value very well in angiography,
however. In angiography, again significantly higher local iodine
concentrations (in the blood) are also necessary, however, such
as can be achieved in mammary tumors. In this respect, the
possible use of this technique for detecting smaller lesions was
not predictable. The process thus is based on the use of digital
image receivers in mammography, which must have site resolution
that is sufficient for this testing method. To achieve this
resolution in the digital image that is necessary for
mammography, it is therefore possible either to work with digital
image receivers of small pixel sizes or to use digital image

receivers in connection with the direct-radiographic magnification technique. Both the contrast resolution and site resolution are considerably improved by the combined use of the magnification technique with digital image receivers. As a result, it is specifically the detection of small lesions that is considerably facilitated. The process is essentially based on the following steps:

- A normal mammogram (pre-contrast image) is recorded.
 The data are stored.
- 2) The patient receives a suitable contrast medium at a sufficient dose -- quickly intravenously injected.
- 3) Starting at 30 seconds after the end of the injection, one or more additional mammograms are recorded and stored.
- 4) The data that are taken under (1) are correlated (preferably subtracted) with the data that are taken under (3), and the result is correspondingly enhanced and put out as a picture.
- optionally, data for speed and for the extent of the increase in contrast medium and for the kinetics of the washing process are calculated and separately visualized.

The invention therefore also relates to a device for projection mammography that is characterized by site resolution that is sufficient for the mammographic testing. This sufficient site resolution is achieved either directly via the resolution capacity of the digital image receiver or is achieved by a

linkage of the digital image receiver and the direct-radiographic magnification technique. The device also contains at least one storage device for the pre-contrast image, at least one storage device for the post-contrast image, at least one computing unit for correlation (especially subtraction) of the various images, and an output device for the calculated mammogram.

Except for the correlation of the time-sequenced images or data records, it is also advantageous to correlate images that were produced with varying radiation energy. Thus, e.g., in the use of bromine-containing compounds according to the invention, an image with a radiation energy of $\xi_1=35~\mathrm{kV}$ and an image with a radiation energy of $\xi_2=25~\mathrm{kV}$ can be made, and the stored images can be correlated with one another -- especially subtracted from one another. In this case, suppression of the normal tissue structures in favor of the opacifying, intravenously fed element is also achieved, since the radiation absorption of the tissue in the selected energies differs from that of the contrast medium. By repeated measurement, the time behavior of the contrast medium concentration can also be detected and evaluated using such a device.

Another subject of the invention is therefore a device for projection mammography that is characterized by at least one storage device for an image at a radiation energy ξ_1 , at least one storage device for an image at a radiation energy ξ_2 , at least one computing unit for correlation of the various images, and an output device for the calculated mammogram.

In standard projection mammography, in each case only one breast is tested. To limit the necessary quantity of contrast medium, it is advantageous in the use according to the invention to test both breasts simultaneously. Devices that allow such testing are not yet known. The subjects of the invention are therefore also devices that are characterized in that they make possible simultaneous testing of both breasts.

Embodiments:

The following examples are to explain the subject of the invention without intending that it be limited to these examples.

Example 1: Phantom Studies

Bismuth-, iodine- and bromine-containing contrast medium solutions ((4S)-4-(ethoxybenzyl)3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanoic acid, bismuth complex, disodium salt, iotrolan (INN) or N-cetyl-N,N,N-trimethylammonium bromide) are produced at a concentration of 9.8 mg of Bi/ml, 6 mg of iodine/ml, or 3.8 mg of Br/ml in 2% agar. The agar gels are cut into layers that are 3 mm, 5 mm, or 10 mm thick. The contrast medium-containing gels as well as a control gel with 2.8 mg of NaCl/ml are integrated into an agar block with a thickness of 5 cm. The entire phantom is x-rayed at 28 kV and 63 mA corresponding to a mammogram, whereby the x-ray radiation in each case has to pass through about 4 cm to 5 cm of contrast medium-free agar and 3 mm to 10 mm of contrast medium-containing agar.

Result: Even the contrast medium-containing agar pieces that are only about 3 mm thick are readily detectable. At an equimolar concentration, bromine is, surprisingly enough, about twice as effective as iodine; bismuth is more than three times as effective as iodine (Figure 1).

Figure 1 shows an x-ray image at 28 kV, 63 mA of an agar phantom with embedded contrast medium-containing agar blocks of:
a left series with a thickness of 5 mm, a center series with a 10

mm thickness, and a right series with a 3 mm thickness. The blocks of the upper series contain 3.8 mg of bromine/ml, those of the center series contain 6 mg of iodine/ml, and those of the lower series contain 9.8 mg of Bi/ml.

The block with NaCl is not visible.

Example 2: Intravenous Contrast Medium Mammography

In a patient, a 1.5 cm x 0.8 cm breast carcinoma was detected by mammography based on structures, microlime, and biopsy. Pre-operatively a check is to be made for multiple foci; in this respect, a first indwelling cannula is placed in the left arm vein (V. cubitalis) of the patient. Projection mammography is repeated before the contrast medium is administered. Immediately after the original image, the infusion of 3 ml/kg of Ultravist(R)-300 (Schering AG, Berlin; active ingredient: iopromide (INN)) begins at a rate of 3 ml/sec. using an automatic injector. The first image after the administration of contrast medium is made 1 minute after the end of the infusion. The positions of the patient and the imaging device remain completely unchanged during this time, just like the imaging conditions with 28 kV of tube voltage and 63 mA.

The images after the injection of the contrast medium show a significantly enlarged area of the contrast medium image relative to the tissue that is defined as the tumor area before the administration of contrast medium, but no additional separate foci that accumulate in the breast.


Claims

- 1. Use of intravenous contrast media for the production of a diagnostic agent for projection mammography.
- 2. Use of an agent according to claim 1, characterized in that the intravenous contrast medium contains iodine as an opacifying element.
- 3. Use of an agent according to claim 1, wherein the intravenous contrast medium contains bromine as an opacifying element.
- 4. Use of an agent according to claim 1, wherein the intravenous contrast medium contains a compound of the elements of atomic numbers 34, 42, 44-52, 54-60, 62-79, 82, or 83.
- 5. Use of an agent according to claim 1, wherein the intravenous contrast medium contains a metal chelate of the elements of atomic numbers 56-60, 62-79, 82, or 83.
- 6. Use of an agent according to claim 1, wherein the intravenous contrast medium has a molecular weight of 10,000 to 80,000 D.
- 7. Use of an agent according to claim 1, wherein the intravenous contrast medium is present in more highly-molecular structures.
- 8. Use of an agent according to claim 7, wherein the intravenous contrast medium is present in the form of molecule associates, liposomes, nano- or microparticles.

- 9. Use of intravenous contrast media according to claim 1, wherein they are present in an x-ray opacity that corresponds to 100 mg of iodine/ml to 500 mg of iodine/ml.
- 10. Use of intravenous contrast media according to claim 2, wherein they are present at a concentration of 100 mg of iodine/ml to 500 mg of iodine/ml.
- 11. Use of intravenous contrast media according to claim 2, wherein they are administered at a dose that corresponds to 150 mg of iodine/kg to 1500 mg of iodine/kg of body weight.
- 12. Use of intravenous contrast media according to claim 3, wherein they are present at a concentration of 100 mg of bromine/ml to 500 mg of bromine/ml.
- 13. Use of intravenous contrast media according to claim 3, wherein they are administered at a dose that corresponds to 100 mg of bromine/kg to 1500 mg of bromine/kg of body weight.
- 14. Use of intravenous contrast media according to claim 4, wherein they are present at a concentration of 10 mmol 2 mol/l.
- 15. Use of intravenous contrast media according to claim 4, wherein they are administered at a dose of 0.1 2 mmol/kg of body weight.
- 16. Use of intravenous contrast media according to claim 5, wherein they are present at a concentration of 10 mmol/l 2 mol/l.
- 17. Use of intravenous contrast media according to claim 5, wherein they are administered at a dose of 0.1 2 mmol/kg of body weight.

PCT/EP98/03658

Fig. 1



7032436410

T-289 P 03/05 F-459

51412B M1

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Includes Reference to PCT International Applications)										
As a belo	w named inventor, I here	by declare that								
My reside	ence, post office address.	and citizenship are as su	ated below next	to my name,						
I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint invente names are listed below) of the subject matter which is claimed and for which a patent is sought of the invention entit										
	USE OF INTRA	VENOUS CONTRAST	MEDIA FOR	PROJECTION MAMMOGRAF	HY					
the specification of which (check only one item below).										
🗓 is attached hereto.										
🛭 was filed as United States application										
	Senal No09/446.32									
	on20 DECEMBER									
	and was amended									
a.	on (if applicable)									
	was filed as PCT international application									
Number <u>PCT/FP98/03658</u>										
gere rateg	on									
F. 1000	and was amended unde									
-14 				(ıf applı	cable)					
on(if applicable)										
I hereby	state that I have reviewed by any amendment refer	ed and understand the content to above.	ontents of the a	bove-identified specification, in	cluding the claims, as					
117			naternal to the ex	camination of this application in	accordance with Title					
37, Code	of Federal Regulations,	\$1.56(a).								
I hereby	claim priority benefits un	der Title 35, United Stat	tes Code §119 or rtificate or of ar	of the following United States Pr by PCT international application	rovisional Application (S) designating at least					
one coun	arry other than the United	l States of America liste	d below and ha	ve also identified below any for nating at least one country other	eign application(2) for					
of Amen	ca filed by me on the sam	e subject matter having a	filing date befo	re that of the application(s) of wh	ich priority is claimed					
PRIOR U.S. PI	ROVISIONAL AND FOREIC	N/PCT APPLICATION(S)	AND ANY PRIOF	RITY CLAIMS UNDER 35 U.S.C. 119	:					
(វ.វ	COUNTRY "CI manae rCl)	application nu	MBFR	DAIE OF FILING (day month year)	PRIORITY CLAIMED UNDER 35 LSC 119					
	Europe	97250190.	2	20 June 1997	\$\delta \range \square \square \square \qquare \square \qquare \qqquare \qqqq \qqqqq \qqqq \qqq \qqqq \qqq \qqqq \qqq \qqqq \qqq \qqqq \qqq \qqqq \qqq \qqqq \qqq \qqqq \qqq \qqqq \qqq \qqqq \qqq \qqqq \qqqqq					
					TYES ONO					
					□ YES □ NO					
					O YES O NO					
	□ YEs □ NO									

ı	EN.	WHITE.	7ELANO	å	BRANIGAN

ATTURNEY'S DOUKET NUMBER Combined Declaration For Patent Application and Power of Attorney (Continued) SCH 1653 (includes Reference to PCT International Applications) I necessy claim the benefit under Title 35, United States Code, \$120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35. United States Code, §112.1 acknowledge the duty to disclose material information as defined in Title 37. Code of Federal Regulations §1.56(a) which occurred between the filing date of the prior application(s) and the national of PCT international filing date of this application US FILING DATE PATENTED ABANDONED US APPLICATION NUMBER

US SERIAL NUMBERS ASSIGNED (Juny) PC [FILING DATE PUT APPLICATION NO

POWER OF ATTORNEY As a named inventor I hereby appoint I William Millen (19,544), John L. White (17,746) Anthony J Zelaro (27,969); Alan E. I Branigan (20,565), John R. Moses (24,983), Harry B. Shubin (32,004). Brion P. Heaney (32,542). Richard J. Traverso (30,595); John A. Sopp (33,103), Richard M. Lebovitz (37,067). John H. Thomas (33,460). Catherine M. Joyce (40,668). James T. Moore (35,619), and Naricy Axelrod (44,014) to prosecute this application and transact all business in the Patent and Trademark Office connected

Send Correspondence to

MILLEN. WHITE, ZELANO & BRANICAN PC Arlington Courthouse Place I Suite 1400 2200 Clarendon Boulevard Arlington, Virginia 22201

Telephone Nu 703/243-6333

Direct Telephone Calls to 703/813-5325

FAMILY NAME FIRST CIVEN NAME SECUND LIVEN NAME FULL NAME OF INVENTOR SPECK 2 0 STATE OR FOREIGN COUNTRY COUNTRY OF CHIZENSHIP CITY RESIDENCE & CITIZENSHIP Germany Cermany 1 Berlin STATE & ZIP CODE/COUNTRY CICY rust uffice SIKEET Furstendamm 20 **ADDRESS** D-13465 Germany Berlin FIRST CIVEN NAME SECUND CIVEN NAME FAMILY NAME PULL NAME OF INVENTOR **VON BRENNDORFF** 2 0 STATE OR FUREIGN COUNTRY COUNTRY OF CITIZENSHIP KESIDENCE & CIFIZENSHIP 2 Germany Germany Braunschweig D-35106 6 Brannschweig POST OFFICE SCREET Germany ADDRESS Hohlbeinstrasse 4 SECOND GIVEN NAME FIRST CIVEN NAME FULL NAME FAMILY NAME OF INVENTOR 2 COUNTRY OF CITIZENSHIP 0 STATE OR FOREIGN COUNTRY KESIDENCE & CITIZENSHIP 3 STATE & ZIP CODE/COUNTRY POST OFFICE SCREET ADDRESS FIRST CIVEN NAME SELUND CIVEN NAME FAMILY NAME FULL NAME OF INVENTOR 2 0 COUNTRY OF CITIZENSBUR RESIDENCE & STATE OR FOREIGN COUNTRY CITIZENSHIP 4 STATE & ZIP CODE/COUNTRY POST OFFICE STREET ADDRESS

Co.	mbined Decl	laration for Patent Applica Tilternational Applications)	ation an	d Power	of Attorney (Continued	i)	SCH 1	.653	
2	FULL NAME OF INVENTOR.	FAMILY NAME		FIRST GIVE	NAME	PECOUN GIAE	NAME		
0 5	MESIDENCE & CITIZENSHIP	cit		STATE OR F	OREICH COUNTRY	COLNIRY OF	LI712E\Smi	P	
	PUST OFFICE ADDRESS	SIRRET		City		STATE & 71PC	ODECOUN	TRY	
-	FULL NAME OF INVENTOR	FAMILY NAME		PIRST GIVE	NAME	SELUND GIVE	NAME		
0	RESIDENCE &	Cily		STATE OR F	OREICH COLHTRY	COFMIKA OF	LITIZENSMI	ı'	
6	POST OFFICE ADDRESS	STREET		ריוא		STATE & ZIP C	のひむてのしゃ	1RY	
2	PULL NAME OF INVENTOR	FAMILY NAME		riksi Give	N NAME	SECOND GIVE	N NAME		
U	RESIDENCE & CHIZENSHIP	Cily		STATE OR F	ORRIG~ COUNTRY	COUNTRY OF	CITIZENSII	P	
7	PUST OFFICE ADDRESS	S:kffl		CITY		2[Ale 12iPC	:UD&/COUN	ΓRΥ	
-,	FUEL NAME OF INVENTOR	FAMILY NAME		First GIVE	NNAME	PELOND CIVE	NAME		
2 = 0 = 8	RESIDENCE & CITIZENSMIP	CITY		SIAIEORF	OREICH COUNTRY	COUNTRY OF	COUNTRY OF CITIZENSMIP		
_ a	POST OFFICE ADDRESS	SUREET		CHY	SIAIE & ZIP C	STATE & ZIP CODECOUNTRY			
,	PULL NAME OF INVENTOR	FAMILY NAME		FIRST CIVE	N VAMÉ	SECOND CIVE	N NAME		
2 (1) (2)	RESIDENCE & CITIZENSIMP	CITY		27ATE UK 1	UKEIGN COUNTRY	COUNTRY OF	CITIZENSAI	P	
	POST OFFICE ADUKESS	SCREET		CITY		SIAIEA ZIP	.udekukn	TRY	
≠ = 2	FULL NAME OF INVENIOR	FAMILY NAME		riksi Give	NAME	SECUND CIVE	n name		
1 50	KESIDENCE &	CitY	· · · · · · · · · · · · · · · · · · ·	STATE OR F	OKEICH COUNTRY	COUNTRY UP	C1112E/581	ll'	
	rost office aduress	S KĒĒ!		CITY		STAIE & ZIF L	טטפיכטטא	7RY	
	believed to be punishable by	re that all statements made herein of the and further that these statem fine or imprisonment, or both, under the validity of the application of	enis were : dei section	made with t i 1001 of Ti	he knowledge that willful fals the 18 of the United States Co	e statements and	i the like :	o made are	
SIG	VATURE OF INVEN	STOR 201	Mare	42, 1 000	SIGNATURE OF INVENTOR	207		DATE	
3161	nature of inven	1FOx 202	DATE		SICNATURE OF INVENTOR	208		DATE	
SIC	na jukė of invėn	110× 203	DATE		SIGNATURE OF INVENTOR	209		DAIÉ	
ŠįG	NATURE OF INVEN	TOR 204	DATE		SIGNATURE OF INVENTOR	210		DAIE	
Silvi	NATURE OF INVEN	10k 205	DATE		SIGNATURE OF INVENTION	211	DAT		
Sicr	YA TUKE OF INVEN	TOK 200	DATE		SIGNATURE OF INVENTOR	515		DAIE	

(if applicable)

1

COMBINED DECLARATION FOR PATENT	APPLICATION AND POWER OF ATTORNEY
(Includes Reference to PCT International Applicat	nons)

VIIGKAT	I S UUCAL	NUMBER
SCH	1653	

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

From-MILLEN, WHITE, ZELANO & BRANIGAN

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plura) names are listed below) of the subject matter which is claimed and for which a patent is sought of the invention entitled.

USE OF INTRAVENOUS CONTRAST MEDIA FOR PROJECTION MAMMOGRAPHY

the specification of which (chec	k only one item below).
----------------------------------	-------------------------

	is allached hereto.	
Ø	was filed as United States application	
	Senal No <u>09/446,328</u>	
	on20 DECEMBER 1999	
	and was amended	
	on	(1f applicable)
Ø	was filed as PCT international application	
	Number PCT/FP98/03658	
	on	
	and was amended under PCT Article 19	

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, \$1.56(a).

I hereby claim priority benefits under Title 35, United States Code §119 of the following United States Provisional Application and of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventur's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed

PRIOR U.S. PROVISIONAL AND FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (If PCI III MALAIM PCI)	application number	DAIE OF FILING (day month year)	PRIORITY CLAIMED UNDER 30 LOL 119
Europe	97250190.2	20 June 1997	ØAT7 □ NO
			□ YES □ NO
			□ YES □ NO
			□ YE3 □ NO
			O YES O 40

Car	mbined Decl	aration Fo	or Patent App	lication at	rd Powe	er of Attorney (Coi	itinued))	SCH 1653	238PUF T	
	designating the disclosed in that the duty to disc	United States Withose prior a	of America that in opplication(s) in the information as de-	stare listed bet he manner pro fined in Title	low and, it ovided by 37. Code	or any United States a asofar as the subject man the first paragraph of Ti of Federal Regulations g date of this application	er of each tic 35. Ur §1.56(4)	i of the cla lited State:	ums of this applie s Code, \$112, 1 ac	tation is not	
	· · · · · · · · · · · · · · · · · · ·	ICATION NOM				LING DATE		TENTED	PENDING	ASANDONED	

									-	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
	PUT APPLICATION	טא אט	PC [Filit	NG DATE		us serial numbers assigned (funy)			ļ		
							_				
			<u> </u>						<u> </u>		
	(27 969); Alan	E. I Braniga	n <u>(20,565),</u> John . 1031 Richard M	R Moses (24)	,983), Hai (067), Jol	William Millen (19,54 ry B. Shubin (32,004), an H. Thomas (33,460), and transact all pusitiess	Břion P. F. Catherine	leancy <u>(32</u> : M. Joyce	(40 668), James	Tiaverso T Moois	
Final Control of the	Send Correspo	j Ž	MILLEN, WHITT Arlington Courth 2200 Clarendon E Arlington, Virgin	ouse Plaza I S Soulevard	& BRANI Suite 1400	<u>CAN PC 1</u> 2 703/	Telephone 243-6333	Nu	Direct 1et 703/813-5325	tephone Calls to	
107	. 1)									
	OF INVENTOR SPECK				FIRST CIVEN NAME UITICH			SECOND CIVEN NAME			
) j	KI SIDENCE & CITY CITIZENSHIP Berlin					STATE OR FOREIGN COUNTRY Germany			COUNTRY OF CHIZENSHIP Germany		
	rušī ufficē	SIKEET	SUREET Furstendamm 20		CITY Berlin			STATE & ZIP CODECOUNTRY			
	PORESS	Furstendam						D-13465 Germany			
	OF INVENTOR	FAMILY NAM		FIRST CIVEN NAME				SECOND GIVEN NAME			
4	KFZIŊEWCE W	L.1Y			STATEOR	FUREICH COUNTRY		COUNTRY	OF CITIZENSMIT		
2	CIFIZENSHIP	Braunschwe	រដ្ឋ		Germany (1)8			Germany			
ø	POST OFFICE	SCREET Hohlbeinstr		CITY			STATE & ZIP CODE/COUNTRY				
2	FULL NAME OF INVENTOR	FAMILY NAM	r		FIRST CIN	EN NAME		SECONU	GIVEN NAME		
0	KESIDENCE L CITIZENSHIP	CHY	11 - A T-A CAMPANAS - 55 - 14 - 3		STATE OR FOREIGN COUNTRY			COUNTRY OF CITIZENSHIP			
	POST OFFICE ADDRESS	SCREET			спу			STATE & ZIP CODE/COUNTRY			
2	FULL NAME OF INVENTOR	FAMILY NAM	E		FIKST GIVEN NAVIE			SECUND CIVEN NAME			
0	RESIDENCE & CITIZENSHIP	LITY			STATEU	R FOREIGN COUNTRY		COUNTRY OF CITIZENSHIP			
	MIST OFFICE ADDRESS	SIREET			כודי			STATE 1.	ZIP CODE/COON (KY	,	

MITORNETS DOCKET NUMBER